Keywords: Research, ASCO, PhRMA, Breast cancer, Trastuzumab emtansine, Roche, Genentech, Boehringer Ingelheim, Afatinib, NSCLC, Johnson & Johnson, Janssem Zytiga, Prostate cancer

Flood of new cancer drug data presented at ASCO; nearly 1,000 being tested

Article | 04 June 2012

• Print This

The annual prestigious American Society of Clinical Oncology (ASCO) meeting taking place in Chicago, as usual, saw a plethora of ...

Enjoying this article? To continue reading you need to login or subscribe.